role of rankl inhibition in osteoporosisrankl抑制在骨质疏松症中的作用.pdfVIP

Available online /content/9/S1/S3 Review Role of RANKL inhibition in osteoporosis Michael McClung Oregon Osteoporosis Center, NE Hoyt Street, Portland, Oregon 97213, USA Corresponding author: Michael McClung, mmcclung@ Published: 29 June 2007 Arthritis Research Therapy 2007, 9(Suppl 1):S3 (doi:10.1186/ar2167) This article is online at /content/9/S1/S3 © 2007 BioMed Central Ltd Abstract about 20% [3]. One-third of hip fractures occur in men. A When the rate of bone resorption exceeds that of bone formation, healthy 50-year-old woman has a 40% to 50% chance of destruction of bone tissue occurs, resulting in a fragile skeleton. The experiencing an osteoporosis-related fracture over the clinical consequences, namely osteoporosis and fragility fractures, remainder of her lifetime, whereas approximately 20% of men are common and costly problems. Treatments that normalize the will experience fragility fractures. balance of bone turnover by inhibiting bone resorption preserve bone mass and reduce fracture risk. The discovery of receptor Caring for patients with these fractures is expensive; the activator of nuclear factor-κB ligand (RANKL) as a pivotal regulator of osteoclast activity provides a new therapeutic target. Early annual direct care expenditure on caring for patients with studies have demonstrated that denosumab, an investigational, osteoporotic fractures was US$12 to 18 billion in 2002 [3]. hig